



## **Enanta Pharmaceuticals to Host Conference Call on November 20 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2017**

November 13, 2017

WATERTOWN, Mass.--(BUSINESS WIRE)--Nov. 13, 2017-- Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA), a chemistry-driven biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal fourth quarter and year ended September 30, 2017, after the U.S. markets close on November 20, 2017. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta's business, including its research and development pipeline.

### **Conference Call and Webcast Information**

To participate in the live conference call, please dial (855) 840-0595 in the U.S. or (518) 444-4814 for international callers. A replay of the conference call will be available starting at approximately 7:30 p.m. ET on November 20, 2017, through 11:59 p.m. ET on November 23, 2017 by dialing (855) 859-2056 from the U.S. or (404) 537-3406 for international callers. The passcode for both the live call and the replay is 6197609. A live audio webcast of the call and replay can be accessed by visiting the "Events and Presentation" section on the "Investors" page of Enanta's website at [www.enanta.com](http://www.enanta.com).

### **About Enanta**

Enanta Pharmaceuticals has used its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery of small molecule drugs for the treatment of viral infections and liver diseases. Two protease inhibitors, paritaprevir and glecaprevir, discovered and developed through Enanta's collaboration with AbbVie, have now been approved in jurisdictions around the world as part of AbbVie's direct-acting antiviral (DAA) regimens for the treatment of hepatitis C virus (HCV) infection, including the U.S.-marketed regimens MAVYRET™ (glecaprevir/pibrentasvir) and VIEKIRA PAK® (paritaprevir/ritonavir/ombitasvir/dasabuvir).

Royalties and milestone payments from the AbbVie collaboration are helping to fund Enanta's research and development efforts, which are currently focused on the following disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). Please visit [www.enanta.com](http://www.enanta.com) for more information.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20171113005560/en/>

Source: Enanta Pharmaceuticals, Inc.

### **Investor:**

Enanta Pharmaceuticals, Inc.  
Carol Miceli, 617-607-0710  
[cmiceli@enanta.com](mailto:cmiceli@enanta.com)